CAMBRIDGE, Mass.--(BUSINESS WIRE)--Curis, Inc. (NASDAQ: CRIS), a drug development company focused on seeking to develop the next generation of proprietary targeted medicines for cancer treatment, announced that a presentation entitled, “A First-in-Human, First-in-Class, Phase I Study of Systemic Hedgehog Pathway Antagonist, GDC-0449, in Patients with Advanced Solid Tumors,” was given by Patricia LoRusso, D. O., yesterday at the American Society of Clinical Oncology (ASCO) Annual Meeting 2008 in Chicago, Illinois. GDC-0449 is being developed by Genentech under a June 2003 collaboration agreement with Curis.
